Chat
Feedback
Settings

Settings

Goto Application

78,549 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 7,855
1.3169544COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS
CA - 10.09.2021
Int.Class C07K 7/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
02Linear peptides containing at least one abnormal peptide link
 Appl.No 3169544 Applicant PHARMA MAR, S.A. Inventor AVILES MARIN, PABLO
The present invention relates to the use of compounds in the treatment of inflammation, preferably inflammation associated with activation of Toll-like receptors. The invention also relates to the use of compounds to treat pathogen-induced inflammation.
2.20230295236COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS
US - 21.09.2023
Int.Class C07K 11/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
11Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
02cyclic, e.g. valinomycins
 Appl.No 17908526 Applicant PHARMA MAR, S.A. Inventor Pablo AVILÉS MARÍN

The present invention relates to the use of compounds in the treatment of inflammation, preferably inflammation associated with activation of Toll-like receptors. The invention also relates to the use of compounds to treat pathogen-induced inflammation.

3.20220211838NUCLEIC ACID BASED COMBINATION VACCINES
US - 07.07.2022
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
 Appl.No 17665704 Applicant CureVac AG Inventor Cornelia OOSTVOGELS

The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.

4.20220211841NUCLEIC ACID BASED COMBINATION VACCINES
US - 07.07.2022
Int.Class A61K 39/295
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
 Appl.No 17665772 Applicant CureVac AG Inventor Cornelia OOSTVOGELS

The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.

5.20240150396INHIBITORS OF CYSTEINE PROTEASES
US - 09.05.2024
Int.Class C07K 5/078
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
06Dipeptides
078the first amino acid being heterocyclic, e.g. Pro, His, Trp
 Appl.No 18280400 Applicant The Texas A&M University System Inventor Thomas D. Meek

Provided herein are pharmaceutical compositions including compounds having Formula (I) in an effective amount to inhibit cysteine protease as well as methods of using thereof.

embedded image

6.WO/2022/187491INHIBITORS OF CYSTEINE PROTEASES
WO - 09.09.2022
Int.Class A61K 38/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
 Appl.No PCT/US2022/018714 Applicant THE TEXAS A& M UNIVERSITY SYSTEM Inventor MEEK, Thomas D.
Provided herein are pharmaceutical compositions including compounds having Formula (I) in an effective amount to inhibit cysteine protease as well as methods of using thereof.
7.20230416692REVERSE GENETIC SYSTEM FOR SARS-COV-2
US - 28.12.2023
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No 17914735 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor PEI-YONG SHI

Certain embodiments of the invention include recombinant reverse genetic systems for SARS-COV-2 virus.

8.WO/2021/211792TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN
WO - 21.10.2021
Int.Class A61K 31/7135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7135Compounds containing heavy metals
 Appl.No PCT/US2021/027404 Applicant GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor KUMAR, Mukesh
The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.
9.WO/2021/195596REVERSE GENETIC SYSTEM FOR SARS-COV-2
WO - 30.09.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/US2021/024532 Applicant XIE, Xuping Inventor XIE, Xuping
Certain embodiments of the invention include recombinant reverse genetic systems for SARS-COV-2 virus.
10.WO/2022/213076METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION
WO - 06.10.2022
Int.Class C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
 Appl.No PCT/US2022/071424 Applicant BAYLOR COLLEGE OF MEDICINE Inventor WANG, Qinghua
Aspects of the present disclosure relate compositions comprising polypeptides or polynucleotides encoding such polypeptides that interact with target proteins such as viral spike proteins, and to methods of their use for treatment and prevention of disease, such as viral infections and/or post-viral infection syndromes.
# -